AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A newborn NOD/SCID/IL2rg-null mouse ~~mammal (excluding human)~~, into which human-derived hematopoietic stem or precursor cells have been transplanted, and which is able to generate immunocompetent cells derived from said human-derived hematopoietic stem or precursor cells and/or physiologically active substances derived from said immunocompetent cells, wherein the immunocompetent cells comprise B cells, T cells and dendritic cells.

2. **(Currently Amended)** An immunodeficient mouse ~~mammal~~ obtained as a result of the breeding of a newborn NOD/SCID/IL2rg-null mouse ~~mammal (excluding human)~~, into which human-derived hematopoietic stem or precursor cells have been transplanted, and which is able to generate immunocompetent cells derived from said human-derived hematopoietic stem or precursor cells and/or physiologically active substances derived from said immunocompetent cells, or a progeny thereof, wherein the immunocompetent cells comprise B cells, T cells and dendritic cells.

3. (Cancelled)

4. **(Currently Amended)** The newborn mouse ~~mammal~~ according to claim 1, wherein the hematopoietic stem or precursor cells are derived from bone marrow, cord blood, or peripheral blood.

5. (Withdrawn) The newborn mammal according to claim 1, wherein the immunocompetent cells further comprise NK cells and NKT cells.

6. **(Currently Amended)** The newborn mouse ~~mammal~~ according to claim 1, wherein the physiologically active substance is a cytokine and/or an immunoglobulin, wherein the immunoglobulin comprises IgG, IgM, IgA and IgD.

7. (Withdrawn) The newborn mammal according to claim 6, wherein the immunoglobulin further comprises IgE.

8. **(Cancelled)**

9. (Withdrawn) A method for producing a mammal capable of generating immunocompetent cells derived from a human and/or physiologically active substances derived from said immunocompetent cells, or a progeny thereof, which is characterized in that it comprises transplantation of human-derived hematopoietic precursor cells or mature hematopoietic cells into an immature immunodeficient mammal (excluding said human).

10. (Withdrawn) The method according to claim 9, wherein the immature immunodeficient mammal is a newborn immunodeficient mammal or a fetal immunodeficient mammal.

11. (Withdrawn) The method according to claim 9, wherein the hematopoietic precursor cells are derived from bone marrow, cord blood, or peripheral blood.

12. (Withdrawn) The method according to claim 9, wherein the immunocompetent cells are at least one selected from the group consisting of B cells, T cells, dendritic cells, NK cells, and NKT cells.

13. (Withdrawn) The method according to claim 9, wherein the physiologically active substance is a cytokine and/or an immunoglobulin.

14. (Withdrawn) The method according to claim 13, wherein the immunoglobulin is any one selected from the group consisting of IgG, IgM, IgA, IgD, and IgE.

15. (Withdrawn) The method according to claim 9, wherein the immunodeficient mammal is an immunodeficient mouse.

16. (Withdrawn) A method for producing a human-derived antibody, which is characterized in that it comprises recovering immunocompetent cells from the mammal according to claim 1, or the mammal or a progeny thereof, culturing said immunocompetent cells in the presence of an antigen or a stimulator, and collecting said human-derived antibody from the obtained culture product.

17. (Withdrawn) The method according to claim 16, wherein the immunocompetent cells are at least one selected from the group consisting of B cells, T cells, dendritic cells, NK cells, and NKT cells.

18. (Withdrawn) A method for producing a human-derived antibody, which is characterized in that it comprises immunizing the mammal according to claim 1, or the mammal or a progeny thereof, with an antigen or a stimulator, and collecting said human-derived antibody from the immunized mammal.

19. (Withdrawn) The method according to claim 18, wherein the antibody is collected from blood plasma or serum.

20. (Withdrawn) A disease-model mammal, which is produced by administering to the mammal according to claim 1, or the mammal or a progeny thereof, any one selected from the group consisting of bacteria, viruses, tumor cells, and tumor antigen peptides, or a progeny thereof.

21. (Withdrawn) The mammal according to claim 20 or a progeny thereof, wherein the disease is an infectious disease.

22. (Withdrawn) A method for screening for an immune-related pharmaceutical, which is characterized in that it comprises administering a test substance to the mammal according to claim 1, or the mammal or a progeny thereof, and evaluating the effectiveness of the test substance.

23. (Withdrawn) The method according to claim 22, wherein the immune-related pharmaceutical is a vaccine.

24. (Withdrawn) A method for producing immunocompetent cells, which is characterized in that it comprises recovering said immunocompetent cells from the mammal according to claim 1, or the mammal or a progeny thereof.

25. – 26. (Cancelled)

27. (Withdrawn) A method for producing immunocompetent cells, which is characterized in that it comprises recovering said immunocompetent cells from the mammal according to claim 20 or a progeny thereof.

28. – 33. (Cancelled)

34. **(Currently Amended)** The immunodeficient mouse ~~mammal~~ according to claim 2, wherein the hematopoietic stem or precursor cells are derived from bone marrow, cord blood, or peripheral blood.

35. (Withdrawn) The immunodeficient mammal according to claim 2, wherein the immunocompetent cells further comprise NK cells and NKT cells.

36. **(Currently Amended)** The immunodeficient mouse ~~mammal~~ according to claim 2, wherein the physiologically active substance is a cytokine and/or an immunoglobulin, wherein the immunoglobulin comprises IgG, IgM, IgA and IgD.

37. (Withdrawn) The immunodeficient mammal according to claim 36, wherein the immunoglobulin further comprises IgE.

38. **(Cancelled)**

39. **(New)** The newborn mouse according to claim 1, wherein the physiologically active substances are antigen-specific human IgG, IgM, and IgA when the mouse is sensitized to an antigen.

40. **(New)** The immunodeficient mouse according to claim 2, wherein the physiologically active substances are antigen-specific human IgG, IgM, and IgA when the mouse is sensitized to an antigen.

41. **(New)** The newborn mouse according to claim 39, wherein the amount of the antigen-specific human IgG in the serum of the mouse is 0.1 to 1.0 x 10^4 μg/ml serum.

42. **(New)** The newborn mouse according to claim 39, wherein the amount of the antigen-specific human IgG in the serum of the mouse is 0.1 to 3.4 x 10^3 μg/ml serum.

43. **(New)** The immunodeficient mouse according to claim 40, the amount of the antigen-specific human IgG in the serum of the mouse is 0.1 to 1.0 x 10^4 μg/ml serum.

44. **(New)** The immunodeficient mouse according to claim 40, wherein the amount of the antigen-specific human IgG in the serum of the mouse is 0.1 to 3.4 x 10^3 μg/ml serum.

45. **(New)** A method for producing a newborn mouse according to claim 1 comprising,

irradiating an immature NOD/SCID/IL2rg-null mouse,

and transplanting human-derived hematopoietic precursor cells or mature hematopoietic cells into the irradiated mouse.

46. **(New)** The newborn mouse according to claim 1, wherein bone marrow tissue extracted from the mouse after it has matured for three months has a ratio of human-derived hematopoietic cells to recipient-derived hematopoietic cells of between 58.8:100 and 90:100.

47. **(New)** The newborn mouse according to claim 1, wherein spleen tissue extracted from the mouse after it has matured for three months has a ratio of human-derived antibody-generating cells to recipient-derived antibody-generating cells of between 47.1:100 and 80:100.

48. **(New)** The newborn mouse according to claim 1, wherein peripheral blood extracted from the mouse after it has matured for three months has a ratio of human-derived antibody-generating cells to recipient-derived antibody-generating cells of between 50.1:100 and 80:100.